🧾 What This Document Is

This is an 8-K filing from Xtant Medical, which companies use to inform investors of major events. This specific filing includes a press release detailing their full-year and fourth-quarter 2025 financial results. It’s a report card showing if the company is growing, making money, and where it’s headed.

🏢 What The Company Does

👉 In simple terms, Xtant Medical makes and sells medical products that help surgeons repair spines and other bones. Think of them as a company that provides the tools and materials—like synthetic bone grafts and collagen patches—used in orthopedic surgeries. They are shifting their focus to their core "biologics" business, which are products that help the body heal itself.

💰 Financial Highlights: A Turnaround Story

This was a transformational year where Xtant moved from losses to profits.

• Revenue Growth: Full-year revenue hit $134.0 million, up 14% from 2024. This growth came from selling more of their core products and some temporary license deals.
• Profitability Achieved: This is the big headline. The company swung to a net income of $5.0 million for the year, compared to a loss of $16.5 million in 2024.
• Improved Margins: Their gross margin (what's left after the cost of making products) improved significantly to 62.9% for the year, up from 58.2%. This means they are keeping more money from each sale.
• Cash Flow Positive: They generated $12.5 million in cash from operations, a huge improvement from using $11.9 million in 2024.

🚀 Key Moves That Reshaped the Company

Xtant made some major strategic moves in 2025 to simplify and strengthen the business.

• Sold Non-Core Assets: They sold off their Coflex® and CoFix products and international hardware business to a company called Companion Spine for $21.4 million in cash. This lets them focus purely on biologics.
• Launched New Products: They introduced two new products: nanOss Strata™ (a next-gen synthetic bone graft) and CollagenX™ (a collagen product for wound healing). This shows they are still innovating.
• Boosted Sales Team: They started adding more sales representatives to the field to grow their core business.

📦 Financial Position: Stronger and Safer

The company's balance sheet looks much healthier now.

• Cash is King: They ended 2025 with $17.3 million in cash, up from just $6.2 million the year before. They also received an additional $10.5 million in early 2026 from the Companion Spine deal.
• Debt Reduced: They used cash to pay down debt. Their long-term debt fell to about $11.2 million (after the early 2026 payment), down from over $22 million.
• Inventory Improved: Inventory levels dropped, which is good—it means they're managing stock better and not tying up as much cash in unsold products.

🔮 What's Next: 2026 Guidance

Management provided a forecast for 2026, which tells us what to expect.

• Revenue Forecast: They expect 2026 revenue to be between $95 million and $99 million. This is lower than 2025, but that’s expected because they sold a chunk of their business (the Coflex assets). They expect the remaining core biologics business to grow.
• Cash Flow Goal: They aim to be free cash flow positive again in 2026.
• No Cash Raise Needed: With over $22 million in cash, the CEO stated they do not need to raise additional capital to run the business, which is a very positive signal.

⚖️ The Big Picture: Strengths & Risks

👍 Strengths:

• Successfully executed a strategic pivot to focus on its core biologics business.
• Achieved a major financial turnaround: profitability and positive cash flow.
• Strengthened its balance sheet with more cash and less debt.
• Actively investing in sales and new products to drive future growth.

⚠️ Risks:

• The near-term revenue drop from the asset sale may worry some investors.
• They operate in the competitive medical device industry.
• Future growth depends heavily on the success of their new product launches and sales force expansion.

🧠 The Analogy

Xtant Medical was like a homeowner who owned a big, complicated house with parts they didn’t use. In 2025, they sold off the unused wing (the non-core assets), used the cash to pay down their mortgage (reduced debt), and renovated the main kitchen (invested in their core biologics business and sales team). Now, they live in a simpler, more efficient, and financially secure home, ready to enjoy it more.

📇 Key Contacts & People

• Investor Relations:
  • Kevin Gardner, LifeSci Advisors: [email protected]
  • Rob Windsor, LifeSci Advisors: [email protected]
• Company Leadership: Sean Browne, President and CEO (quoted in the release).

🧩 Final Takeaway

Xtant Medical's 2025 was all about a profitable transformation. By selling non-core assets and focusing on its higher-margin biologics products, the company turned a significant loss into a profit, generated strong cash, and built a solid financial foundation for 2026, even though reported revenue will temporarily decline.